Label-free integrative pharmacology on-target of opioid ligands at the opioid receptor family

BMC Pharmacology and Toxicology

Volumn 14, Issue , 2013, Pages

  Morse, Megan ^a   Sun, Haiyan ^b   Tran, Elizabeth ^b   Levenson, Robert ^a   Fang, Ye ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b Corning Inc ^*  (United States)

Author keywords

Functional selectivity; Label free biosensor; Opioid receptor

Indexed keywords

3 [1 (3,4 DICHLORO N METHYLPHENYLACETAMIDO) 2 (1 PYRROLIDINYL)ETHYL]PHENOXYACETIC ACID; 3,4 DICHLORO N METHYL N [1 PHENYL 2 (1 PYRROLIDINYL)ETHYL]BENZENEACETAMIDE; 4 [(3,4 DICHLOROPHENYL)ACETYL] 3 (1 PYRROLIDINYLMETHYL) 1 PIPERAZINECARBOXYLIC ACID METHYL ESTER; ALPHA NEOENDORPHIN; DELTA OPIATE RECEPTOR; DELTAKEPHALIN; DELTORPHIN; DYNORPHIN A; DYNORPHIN B; ENDOMORPHIN 1; ENDOMORPHIN 2; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 METHIONINOL SULFOXIDE]; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; KAPPA OPIATE RECEPTOR; LEUCINE ENKEPHALIN; LEUCINE ENKEPHALIN[2 DEXTRO SERINE 6 THREONINE]; LEVALLORPHAN; LIGAND; METENKEPHALIN; MORPHICEPTIN; MU OPIATE RECEPTOR; NALTRINDOLE; NOCICEPTIN; OPIATE; OPIATE RECEPTOR; OPIOID LIKE RECEPTOR 1; TYROSYL DEXTRO ARGINYLPHENYLALANYLLYSINAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CELL ASSAY; CONTROLLED STUDY; DYNAMIC MASS REDISTRIBUTION ASSAY; EMBRYO; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LABEL FREE INTEGRATIVE PHARMACOLOGY ON TARGET; NEUROBLASTOMA CELL; PHARMACOLOGICAL PROCEDURES; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; CELL LINE; GENETIC PROCEDURES; METABOLISM;

BIOSENSING TECHNIQUES; CELL LINE; HUMANS; LIGANDS; RECEPTORS, OPIOID;

MLCS; MLOWN;

EID: 84879825146     PISSN: 20506511     EISSN: None     Source Type: Journal    
DOI: 10.1186/2050-6511-14-17     Document Type: Article

References (54)

1. Kenakin T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 2005, 4:919-927. 10.1038/nrd1875, 16264435.
2. Mailman RB. GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 2007, 28:390-396. 10.1016/j.tips.2007.06.002, 2958218, 17629962.
3. Galandrin S, Oligny-Longpre G, Bouvier M. The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci 2007, 8:423-430.
4. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007, 320:1-13.
5. Neve KA. Functional selectivity of G protein-coupled receptor ligands 2009, New York: Humana.
6. Raehal KM, Schmid CL, Groer CE, Bohn LM. Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev 2011, 63:1001-1019. 10.1124/pr.111.004598, 3186080, 21873412.
7. Law PY, Wong YH, Loh HH. Molecular mechanisms and regulation of opioid receptor signaling. Ann Rev Pharmacol Toxicol 2000, 40:389-430.
8. Kenakin T, Miller LJ. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 2010, 62:265-304. 10.1124/pr.108.000992, 2879912, 20392808.
9. Swinney DC, Anthony J. How were new medicines discovered?. Nat Rev Drug Discov 2011, 10:507-519. 10.1038/nrd3480, 21701501.
10. Fang Y, Ferrie AM, Fontaine NH, Mauro J, Balakrishnan J. Resonant waveguide grating biosensor for living cell sensing. Biophys J 2006, 91:1925-1940. 10.1529/biophysj.105.077818, 1544314, 16766609.
11. Fang Y, Li G, Ferrie AM. Non-invasive optical biosensor for assaying endogenous G protein-coupled receptors in adherent cells. J Pharamcol Toxicol Methods 2007, 55:314-322.
12. Kenakin T. Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nat Rev Drug Discov 2009, 8:617-626. 10.1038/nrd2838, 19609267.
13. Fang Y. Label-free receptor assays. Drug Discov Today Technol 2010, 7:e5-e11.
14. Scott CW, Peters MF. Label-free whole-cell assays: expanding the scope of GPCR screening. Drug Discov Today 2010, 15:704-716. 10.1016/j.drudis.2010.06.008, 20601093.
15. Ferrie AM, Sun H, Fang Y. Label-free integrative pharmacology on-target of drugs at the β2-adrenergic receptor. Sci Rep 2011, 1:33. 3216520, 22355552.
16. Morse M, Tran E, Sun H, Levenson R, Fang Y. Ligand-directed functional selectivity at the mu opioid receptor revealed by label-free integrative pharmacology on-target. PLoS One 2011, 6:e25643. 10.1371/journal.pone.0025643, 3189208, 22003401.
17. He L, Fong J, von Zastrow M, Whistler JL. Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell 2002, 108:271-282. 10.1016/S0092-8674(02)00613-X, 11832216.
18. Tsao PI, von Zastrow M. Type-specific sorting on G protein-coupled receptors after endocytosis. J Biol Chem 2000, 275:11130-11140. 10.1074/jbc.275.15.11130, 10753919.
19. Li JG, Zhang F, Jin XL, Liu-Chen LY. Differential regulation of the human κ opioid receptor by agonists: etorphin and levorphanol reduced dynorphin-A and U50,488H-induced internalization and phosphorylation. J Pharmacol Exp Ther 2003, 305:531-540. 10.1124/jpet.102.045559, 12606694.
20. Yu VC, Elger S, Duan DS, Lameh J, Sadée W. Regulation of cyclic AMP by the μ-opioid receptor in human neuroblastoma SH-SY5Y cells. J Neurochem 1990, 55:1390-1396. 10.1111/j.1471-4159.1990.tb03151.x, 1697894.
21. Kazmi SMI, Mishra RK. Comparative pharmacological properties and functional coupling of mu and delta opioid receptor sites in human neuroblastoma SH-SY5Y cells. Mol Pharmacol 1987, 32:109-118.
22. Zadina JE, Harrison LM, Ge LJ, Kastin AJ, Chang SL. Differential regulation of mu and delta opiate receptors by morphine, selective agonists and antagonists and differentiating agents in SH-SY5Y human neuroblastoma cells. J Pharmacol Exp Therap 1994, 270:1086-1096.
23. Du YL, Elliot K, Pan YX, Pasternak GW, Inturrisi CE. A splice variant of the mu opioid receptor is present in human SHSY-5Y cells. Soc Neurosci Asbtr 1997, 23:1206.
24. Pan YX. Diversity and complexity of the mu opioid receptor gene: alternative pre-mRNA splicing and promoters. DNA Cell Biol 2005, 24:736-750. 10.1089/dna.2005.24.736, 16274294.
25. Gris P, Gauthier J, Cheng P, Gibson DG, Gris D. A novel alternatively spliced isoform of the mu-opioid receptor: functional antagonism. Mol Pain 2010, 6:33. 10.1186/1744-8069-6-33, 2894766, 20525224.
26. Mayer P, Tischmeyer H, Jayasinghe M, Bonnekoh B, Gollnick H. A δ opioid receptor lacking the third cytoplasmic loop is generated by atypical mRNA processing in human malignomas. FEBS Lett 2000, 480:156-160. 10.1016/S0014-5793(00)01929-3, 11034319.
27. Fang Y, Ferrie AM. Label-free optical biosensor for ligand-directed functional selectivity of acting on β2 adrenoceptor in living cells. FEBS Lett 2008, 582:558-564. 10.1016/j.febslet.2008.01.021, 18242178.
28. Kenakin T. Being mindful of seven-transmembrane receptor 'guests' when assessing agonist selectivity. Br J Pharmacol 2010, 160:1045-1047. 10.1111/j.1476-5381.2010.00764.x, 2936014, 20590598.
29. Barbieri JT, Cortina G. ADP-ribosyltransferase mutations in the catalytic S-1 subunit of pertussis toxin. Infect Immun 1988, 56:1934-1941. 259504, 3135265.
30. Gill DMM, Meren R. ADP-ribosylation of membrane proteins catalyzed by cholera toxin: basis of the activation of adenylate cyclase. Proc Natl Acad Sci USA 1978, 75:3050-3054. 10.1073/pnas.75.7.3050, 392711, 210449.
31. Tran E, Fang Y. Label-free optical biosensor for probing integrative role of adenylyl cyclase in G protein-coupled receptor signaling. J Recept Signal Transduct Res 2009, 29:154-162. 10.1080/10799890903052544, 19604131.
32. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008, 26:127-132. 10.1038/nbt1358, 18183025.
33. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011, 29:1046-1051. 10.1038/nbt.1990, 22037378.
34. Bruchas MR, Chavkin C. Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacology 2010, 210:137-147. 10.1007/s00213-010-1806-y, 20401607.
35. Fang Y. The development of label-free cellular assays for drug discovery. Exp Opin Drug Discov 2011, 6:1285-1298.
36. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-14868. 10.1073/pnas.95.25.14863, 24541, 9843981.
37. Fang Y. Probing cancer signaling with resonant waveguide grating biosensors. Exp Opin Drug Discov 2010, 5:1237-1248.
38. Gehlenborg N, O'Donoghue SI, Baliga NS, Goesmann A, Hibbs MA. Visualization of omics data for systems biology. Nat Methods 2010, 7:S56-S68. 10.1038/nmeth.1436, 20195258.
39. PDSP Ki database. http://pdsp.med.unc.edu/pdsp.php.
40. Dietis N, Rowbotham DJ, Lambert DG. Opioid receptor subtypes: fact or artifact?. Br J Anaesthesia 2011, 107:8-18. 37.
41. Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 1996, 48:567-592.
42. Jordan BA, Trapaidze N, Gomes I, Nivarthi R, Devi LA. Oligomerization of opioid receptors with β2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proc Natl Acad Sci USA 2001, 98:343-348. 14592, 11134510.
43. Jordan BA, Devi LA. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 1999, 399:697-700. 10.1038/21441, 3125690, 10385123.
44. Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE. A role for heterodimerization of μ and δ opioid receptors in enhancing morphine analgesia. Proc Natl Acad Sci USA 2004, 101:5135-5139. 10.1073/pnas.0307601101, 387386, 15044695.
45. van Rijn RM, Whistler JL, Waldhoer M. Opioid-receptor-heteromer-specific trafficking and pharmacology. Curr Opin Pharmacol 2010, 10:73-79. 10.1016/j.coph.2009.09.007, 2900797, 19846340.
46. Nelson CP, Challiss RA. " Phenotypic" pharmacology: the influence of cellular environment on G protein-coupled receptor antagonist and inverse agonist pharmacology. Biochem Pharmacol 2007, 73:737-751. 10.1016/j.bcp.2006.09.005, 17046719.
47. Kinzer-Ursem TL, Linderman JJ. Both ligand- and cell-specific parameters control ligand agonism in a kinetic model of G protein-coupled receptor signaling. PLoS Comput Biol 2007, 3:e6. 10.1371/journal.pcbi.0030006, 1769407, 17222056.
48. Tran E, Sun H, Fang Y. Dynamic mass redistribution assays decodes surface influence on signaling of endogenous purinergic receptors. Assay Drug Dev Technol 2012, 10:37-45. 10.1089/adt.2011.0392, 3277731, 22066912.
49. Kenakin T. The potential for selective pharmacological therapies through biased receptor signaling. BMC Pharmacol Toxicol 2012, 13:3. 3506267, 22947056.
50. Sun Y, Huang J, Xiang Y, Bastepe M, Juppner H. Dosage-dependent switch from G protein-coupled to G protein-independent signaling by a GPCR. EMBO J 2007, 26:53-64. 10.1038/sj.emboj.7601502, 1782364, 17170700.
51. Giraldo J. On the fitting of binding data when receptor dimerization is suspected. Br J Pharmacol 2008, 155:17-23. 10.1038/bjp.2008.234, 2527846, 18536745.
52. Peters MF, Scott CW. Evaluating cellular impedance assays for detection of GPCR pleiotropic signaling and functional selectivity. J Biomol Screen 2009, 14:246-255. 10.1177/1087057108330115, 19211780.
53. McLaughlin JN, Shen L, Holinstat M, Brooks JD, DiBenedetto E, Hamm HE. Functional selectivity of G protein signaling by agonist peptides and thrombin for the protease-activated receptor-1. J Biol Chem 2005, 280:25048-25059. 10.1074/jbc.M414090200, 15878870.
54. Goral V, Jin Y, Sun H, Ferrie AM, Wu Q, Fang Y. Agonist-directed desensitization of the β2-adrenergic receptor. PLoS One 2011, 6:e19282. 10.1371/journal.pone.0019282, 3082563, 21541288.